| 注册
首页|期刊导航|中国药房|中美日仿制药一致性评价政策比较研究

中美日仿制药一致性评价政策比较研究

王青宇 杨悦

中国药房2017,Vol.28Issue(25):3457-3460,4.
中国药房2017,Vol.28Issue(25):3457-3460,4.DOI:10.6039/j.issn.1001-0408.2017.25.01

中美日仿制药一致性评价政策比较研究

Comparative Study on the Policies of Generic Drug Consistency Evaluation in China,America and Japan

王青宇 1杨悦2

作者信息

  • 1. 沈阳药科大学工商管理学院,沈阳 110016
  • 2. 郑州大学药学院,郑州 450001
  • 折叠

摘要

Abstract

OBJECTIVE:To study the consistency policies of generic drugs in China,America and Japan comparatively,and provide reference for perfecting quality and efficacy consistency evaluation of generic drugs in China. METHODS:"Generic drug""Consistency evaluation""Quality evaluation""DESI"were used as keywords to search the related literatures or information of ge-neric drugs published or reported in CNKI,Web of Science,Elsevier,Springer database and USA FDA website during Jan. 1st, 1950-Jun. 30th,2016. And comparative analysis was conducted for the historical background,evaluation methods and policy influ-ences of consistency policies of generic drugs in China,America and Japan. RESULTS:There were differences in the historical background,evaluation methods,major participants and policy influences of consistency policies of generic drugs in China,Ameri-ca and Japan. The evaluation for generic drugs in USA was reevaluation of the drugs effectiveness under the history of drug registra-tion regulation was imperfect. With experts'review,it was evaluated based on FDA,enterprises,scientific literature evidence and experts review. Main evaluation method was in vitro dissolution test in Japan. The consistency evaluation of generic drug in China focused on the generic drug marketing authorization,mainly using in vivo bioequivalence. And the standards of reference prepara-tions were from the basically similar drugs to the original drugs. CONCLUSIONS:Compared with innovation-based countries like America and Japan,the availability of reference preparations in China is low,and policy environment is more complex. China should further improve the laws and regulations,giving reasonable buffer period,considering the diversity of evaluation methods, exemptions in special circumstances and current situation of pharmaceutical industry,paying attention to the balance between techni-cal supervision and system supervision.

关键词

仿制药/中国/美国/日本/一致性评价/比较研究/生物等效性

Key words

Generic drugs/China/America/Japan/Consistency evaluation/Comparative study/Bioequivalence

分类

医药卫生

引用本文复制引用

王青宇,杨悦..中美日仿制药一致性评价政策比较研究[J].中国药房,2017,28(25):3457-3460,4.

中国药房

OA北大核心CSTPCD

1001-0408

访问量0
|
下载量0
段落导航相关论文